Diabetes Mellitus Type II Clinical Trial
Official title:
A Primary Care, EHR- Based Strategy to Promote Safe and Appropriate Drug Use
Verified date | September 2016 |
Source | Northwestern University |
Contact | n/a |
Is FDA regulated | No |
Health authority | United States: Institutional Review Board |
Study type | Interventional |
This study seeks to evaluate a low-literacy strategy in a primary health care setting for
promoting safe and effective prescription medication use among English and Spanish-speaking
patients with diabetes.
The investigators hypothesize that in comparison with patients receiving standard care, the
patients that received the Electronic Health Record (EHR) strategy will 1) demonstrate
better understanding of how to safely dose out their medication regimen; 2) have fewer
discrepancies in their medication lists; 3) take their medication regimen more efficiently;
4) have greater adherence to their medication regimen.
Status | Completed |
Enrollment | 541 |
Est. completion date | September 2016 |
Est. primary completion date | August 2016 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years to 90 Years |
Eligibility |
Inclusion Criteria: - 18-years old or older; - have a diagnosis of diabetes mellitus either by ICD-billing codes or indicative medications; - are prescribed at least (3) chronic condition medications according to the EHR medication list; - are English or Spanish-speaking; - have no imminent intention to move or change clinics within the next year; - score 4 or higher on the six-question screener based on the Mini-Mental Status Exam; - are primarily responsible for administering their own medications; - prescribed a new chronic condition medication (including refills, and change in titrations) during their clinic visit and day. Exclusion Criteria: - under age of 18 years-old; - does not speak English or Spanish; - dependent on assistance for medication administration; - scored less than 4 on the six-question screener; - not prescribed a new medication or changed medication at clinical appointment; |
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research
Country | Name | City | State |
---|---|---|---|
United States | Northwestern University | Chicago | Illinois |
United States | University of Illinois at Chicago | Chicago | Illinois |
Lead Sponsor | Collaborator |
---|---|
Northwestern University | University of Illinois at Chicago |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Medication adherence | We will determine to what extent presenting low-literacy information about prescription medicines to patients with diabetes affects their adherence to a medication regimen compared to patients under standard care. Adherence for each prescription medication will be measured through multiple methodologies. |
One month after patients receive intervention materials | No |
Secondary | Clinical outcomes-systolic blood pressure, HbA1, and LDL cholesterol. | We will investigate our strategy's impact on intermediary clinical outcomes including systolic blood pressure for patients with hypertension, HbA1 for patients with diabetes, and LDL cholesterol for patients with hyperlipidemia, through chart extraction at pre and post-intervention. | Baseline interview and after 6 months | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Enrolling by invitation |
NCT02261545 -
The Effect of n-3 Fatty Acid Supplementation on Serum Levels, and Gene Expression of type2 Diabetes Patient
|
Phase 4 | |
Completed |
NCT02028091 -
Diabetes Mellitus - A Diagnosis Trial by Means of Non Invasive Measurements
|
N/A | |
Completed |
NCT01684813 -
VERifynow in DIabetes Non-responsiveness: a Study on Switching From Clopidogrel to Prasugrel
|
Phase 4 | |
Completed |
NCT01252524 -
Effect of Calcium Polycarbophil on Type II Diabetes Mellitus Control: a Randomized Double-blind Study
|
N/A | |
Recruiting |
NCT01311401 -
Predictors of Future Type 2 Diabetes Mellitus in Circassians Minority in Israel
|
N/A | |
Completed |
NCT00563225 -
20 Week Bridging Study in Type II DM
|
Phase 3 | |
Recruiting |
NCT01565096 -
Effect of Adding Vildagliptin on Beta Cell Function and Cardiovascular Risk Markers in Patients With Moderate Metabolic Control During Metformin Monotherapy
|
Phase 4 | |
Completed |
NCT00151697 -
LANN-study: Lantus, Amaryl, Novorapid, Novomix Study
|
Phase 3 | |
Withdrawn |
NCT01453751 -
Safety and Effects of Autologous Adipose-Derived Stromal Cells Delivered in Patients With Type II Diabetes
|
N/A | |
Not yet recruiting |
NCT01775059 -
Collection of Performance Data From the Integrated Sensor and Infusion Set. TRIAL 4
|
N/A | |
Completed |
NCT01281098 -
Prospective, Randomized, Open Label, Phase II Study to Assess Efficacy and Safety of Macugen® (Pegaptanib 0.3 mg Intravitreal Injections) Plus Panretinal Photocoagulation and PRP (Monotherapy) in the Treatment With High Risk PDR.
|
Phase 2 | |
Completed |
NCT02036372 -
Perioperative Insulin, GIK or GLP-1 Treatment in Diabetes Mellitus
|
N/A | |
Completed |
NCT03258840 -
EPA Supplementation on Vascular Inflammation, and Gene Expression of PON2 in Patients With Type II Diabetes Mellitus
|
N/A | |
Active, not recruiting |
NCT01386801 -
Multicenter Research Study to Build a Repository to Study Chronic Diseases in Indiana
|
N/A | |
Completed |
NCT02144948 -
Investigation of the Effect of E.-Coli-Nissle as Supporting Therapy to Standard Care of Diabetes Mellitus Type II
|
Phase 3 |